0.627
-0.01 (-1.72%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Tiziana Life Sciences Ltd | 混合的 | 混合的 |
AIStockmoo 评分
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | 3.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -2.5 |
| 相对估值 | NA |
| 财务健康 | -2.1 |
| 宏观环境 | -1.3 |
| AI Insight | NA |
| AI Technical | NA |
| 平均 | -0.34 |
|
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 43.06% |
| 机构持股比例 | 2.73% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Mid-American Wealth Advisory Group, Inc. | 30 Sep 2026 | 448,667 |
| Venture Visionary Partners Llc | 30 Sep 2026 | 20,000 |
该时间范围内无数据。
该时间范围内无数据。
投资组合